A Case of Allopurinol Hypersensitivity Syndrome with Esophageal Ulcer Bleeding.
- Author:
Jung Hee KIM
1
;
Sang Heon SONG
;
Dong Won LEE
;
Soo Bong LEE
;
Ihm Soo KWAK
Author Information
1. Department of Internal Medicine, College of Medicine, Pusan National University, Busan, Korea. iskwak@pusan.ac.kr
- Publication Type:Case Report
- Keywords:
Allopurinol;
Hypersensitivity;
Hyperuricemia
- MeSH:
Allopurinol*;
Arthritis, Gouty;
Biochemistry;
Blood Cell Count;
Colchicine;
Diagnosis;
Disseminated Intravascular Coagulation;
Eosinophilia;
Exanthema;
Fever;
Gastrointestinal Tract;
Gout;
Hemorrhage*;
Hepatitis;
Humans;
Hypersensitivity*;
Hyperuricemia;
Immunization, Passive;
Incidence;
Leukocytosis;
Middle Aged;
Prognosis;
Renal Insufficiency;
Sepsis;
Skin;
Stevens-Johnson Syndrome;
Ulcer*
- From:Korean Journal of Nephrology
2006;25(4):669-673
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Allopurinol, a commonly prescribed medicine for the management of gout and hyperuricemia, may induce life-threatening hypersensitivity characterized by fever, eosinophilia, hepatitis, renal failure, and skin eruptions such as Stevens-Johnson syndrome or toxic epidermal necrolysis. Stevens-Johnson syndrome may rarely affect the gastrointestinal tract, associated with a poor prognosis. We have experienced a patient having allopurinol hypersensitivity syndrome (AHS) with esophageal ulcer bleeding. A 64-year-old man was admitted with ten-day history of widespread rash and fever. Six weeks before admission, he had symptoms of gouty arthritis, and he was treated with allopurinol and colchicine for 10 days. Complete blood count showed leukocytosis with eosinophilia and blood biochemistry showed impaired renal and hepatic function. The diagnosis of an AHS with Stevens-Johnson syndrome was made from the history and the typical clinical feature. Despite adequate hydration, steroid and immunoglobulin therapy, severe esophageal ulcer bleeding, sepsis and disseminated intravascular coagulation had been developed and the patient died 33 days after admission. Until now, there is no specific treatment for the AHS. The only means of minimizing the incidence of AHS is to limit the allopurinol therapy to accepted indications and to adjust the dosage for the patient's renal function.
